American Medical Association

Mixed experience with the Sunshine Act

Monday, August 1, 2016

Pharmaceutical companies have finished submitting the third batch of data detailing their financial relationships with physicians and teaching hospitals under the Open Payments program, also referred to as the Physician Payment Sunshine Act. Investigators now face the prospect of implementing sophisticated new processes and systems that can track and verify clinical research grant payment information.

[Read More]

Lack of clinical data overshadows opioid prescribing guidelines

Sunday, May 1, 2016

On March 18, 2016, the Centers for Disease Control (CDC) in Atlanta released its guidelines for prescribing opioids for chronic pain in outpatient settings outside of active cancer treatment, palliative care, and end-of-life care. The results were instantly controversial. While no one argues that opioid addiction has become a health crisis, critics claim that a scarcity of clinical trial data undermine the guidelines and could even lead to patients being harmed.

[Read More]

Dr. Anita J. Chawla joins CytRx board of directors

Thursday, March 12, 2015

CytRx, a biopharmaceutical R&D company specializing in oncology, has appointed Anita J. Chawla, Ph.D., to its board of directors. Chawla brings over 25 years of experience as an economist in the health care industry to CytRx, with a proven track record helping pharmaceutical, biotechnology, medical device and diagnostic companies achieve their product development and commercialization objectives.

[Read More]